Vitamin D 3 supplementation decreases a unique circulating monocyte cholesterol pool in patients with type 2 diabetes

Cross-sectional studies indicate consistent associations between low 25(OH)D concentration and increased risk of cardiovascular disease (CVD), but results of randomized control trials (RCTs) are mixed. However, the majority of the RCTs do not focus on type 2 diabetics, potentially obscuring the effe...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of steroid biochemistry and molecular biology 2018-03, Vol.177, p.187
Main Authors: Riek, Amy E, Oh, Jisu, Darwech, Isra, Worthy, Veronica, Lin, Xiaobo, Ostlund, Jr, Richard E, Zhang, Rong M, Bernal-Mizrachi, Carlos
Format: Article
Language:English
Subjects:
CD36 Antigens - metabolism
Cholecalciferol - administration & dosage
Cholesterol - metabolism
Diabetes Mellitus, Type 2 - diet therapy
Diabetes Mellitus, Type 2 - metabolism
Dietary Supplements
Double-Blind Method
Endoplasmic Reticulum Stress - drug effects
Female
Humans
Male
Middle Aged
Monocytes - drug effects
Monocytes - metabolism
Vitamins - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cross-sectional studies indicate consistent associations between low 25(OH)D concentration and increased risk of cardiovascular disease (CVD), but results of randomized control trials (RCTs) are mixed. However, the majority of the RCTs do not focus on type 2 diabetics, potentially obscuring the effects of vitamin D in this population. In vitro 1,25(OH) D downregulates macrophage cholesterol deposition, but the in vivo effects are unknown. To explore potential mechanisms of the effects of vitamin D on CVD risk in patients with type 2 diabetes, we isolated monocytes in a subset of 26 patients from our RCT of diabetics with baseline serum 25(OH)D
ISSN:1879-1220
DOI:10.1016/j.jsbmb.2017.09.011